Biodexa Pharmaceuticals Plc (BDRX)

NASDAQ: BDRX · IEX Real-Time Price · USD

0.897

+0.003 (0.35%)

At close: Jul 2, 2024, 4:00 PM

0.920

+0.023 (2.56%)

After-hours: Jul 2, 2024, 7:55 PM EDT

Biodexa Pharmaceuticals Cash Flow Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2013
Net Income	-7.08	-7.66	-5.46	-22.19	-10.09	Upgrade
Depreciation & Amortization	0.28	0.34	0.4	1.21	1.28	Upgrade
Share-Based Compensation	0.03	0.12	0.09	-0.4	-0.03	Upgrade
Other Operating Activities	-0.9	-0.53	-2.2	10.13	0.43	Upgrade
Operating Cash Flow	-7.67	-7.73	-7.17	-11.26	-8.41	Upgrade
Capital Expenditures	-0.02	-0.04	-0.28	-0.07	-0.31	Upgrade
Acquisitions	-	-	0	0	-0.95	Upgrade
Change in Investments	-0.08	-0.21	0	0	0	Upgrade
Other Investing Activities	-0.16	0.03	-	2.64	-2.55	Upgrade
Investing Cash Flow	-0.27	-0.22	-0.28	2.57	-3.81	Upgrade
Share Issuance / Repurchase	10.43	0.24	9.04	9.74	14.11	Upgrade
Debt Issued / Paid	-0.19	-0.18	-0.22	-6.44	3.41	Upgrade
Other Financing Activities	-0.01	-0.02	-0.02	-0.22	1.22	Upgrade
Financing Cash Flow	10.23	0.05	8.81	3.08	18.73	Upgrade
Exchange Rate Effect	0	0	-0.01	0.26	0.15	Upgrade
Net Cash Flow	3.14	-7.22	2.52	-3.64	8.44	Upgrade
Free Cash Flow	-7.69	-7.77	-7.44	-11.32	-8.72	Upgrade
Free Cash Flow Margin	-2019.16%	-1111.30%	-1287.72%	-3300.58%	-1293.62%	Upgrade
Free Cash Flow Per Share	-11.07	-630.95	-944.04	-3319.49	-5700.17	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).